Drugs / UCAR T-cells
UCAR T-cells
also known as
universal allogeneic anti-CD19/BCMA CAR T-cells
Cell therapy targets CD19
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06920433 | Apr 2025 → Apr 2026 overdue | systemic lupus erythematosus | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06920446 | Apr 2025 → Apr 2026 overdue | autoimmune hemolytic anemia | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06933563 | Apr 2025 → Apr 2026 overdue | myasthenia gravis | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06733610 | Dec 2024 → Feb 2026 overdue | autoimmune hemolytic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05639179 | Dec 2022 → Dec 2024 | B-cell acute lymphoblastic leukemia | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07155369 | Mar 2025 → Sep 2026 expected | systemic lupus erythematosus, systemic sclerosis | The Affiliated Hospital of Xuzhou Medical University | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCAR T-cells | “A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.” NCT06733610 ↗5“A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06920446 ↗ “A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06920433 ↗ “A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06933563 ↗ |
| Known as | universal allogeneic anti-CD19/BCMA CAR T-cells | “A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06920446 ↗1“A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06920433 ↗ |
| Modality | Cell therapy | “universal CAR-T(UCAR-T) cells targeting CD19” NCT05639179 ↗ |
| Route | Intravenous | “UCAR-T Cellswill be administered by vein” NCT05639179 ↗ |
| Target | CD19 | “universal CAR-T(UCAR-T) cells targeting CD19” NCT05639179 ↗ |